| A cerebellar degeneration-related protein 2-like cell-based assay for anti-Yo detection in patients with paraneoplastic cerebellar degeneration. | A cerebellar degeneration-related protein 2-like cell-based assay for anti-Yo detection in patients with paraneoplastic cerebellar degeneration.
Erikstad KI, Herdlevaer I, Peter E, Haugen M, Totland C, Vedeler C. | 05/23/2023 |
| MicroRNA 452 regulates ASB8, NOL8, and CDR2 expression in colorectal cancer cells. | MicroRNA 452 regulates ASB8, NOL8, and CDR2 expression in colorectal cancer cells.
Mo JS, Chae SC. | 09/4/2021 |
| Our data pinpointed the enrichment of acquired immune response, particularly high density of CD8+ lymphocytes, and high-level expression of CDR-related antigens in anti-Yo paraneoplastic cerebellar degeneration ovarian tumours. | Transcriptomic immune profiling of ovarian cancers in paraneoplastic cerebellar degeneration associated with anti-Yo antibodies.
Vialatte de Pémille C, Berzero G, Small M, Psimaras D, Giry M, Daniau M, Sanson M, Delattre JY, Honnorat J, Desestret V, Alentorn A., Free PMC Article | 08/17/2019 |
| Paraneoplastic cerebellar degenerations with anti-Yo antibodies (Yo-PCD) tumors differed from the 116 control tumors by more abundant T and B cells infiltration occasionally organized in tertiary lymphoid structures harboring CDR2L protein deposits. 65% of Yo-PCD tumors cohort presented at least one somatic mutation in CDR2 and CDR2L with a predominance of missense mutations. | Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration.
Small M, Treilleux I, Couillault C, Pissaloux D, Picard G, Paindavoine S, Attignon V, Wang Q, Rogemond V, Lay S, Ray-Coquard I, Pfisterer J, Joly F, Du Bois A, Psimaras D, Bendriss-Vermare N, Caux C, Dubois B, Honnorat J, Desestret V. | 07/6/2019 |
| Both cerebellar degeneration related protein 2 (CDR2) and cerebellar degeneration-related antigen CDR2L (CDR2L) are more widely expressed than previously thought, both in normal and cancerous tissues. | Cerebellar degeneration-related proteins 2 and 2-like are present in ovarian cancer in patients with and without Yo antibodies.
Raspotnig M, Haugen M, Thorsteinsdottir M, Stefansson I, Salvesen HB, Storstein A, Vedeler CA. | 11/11/2017 |
| the role of cdr2 in experimental models of Parkinson's disease, is reported. | Proteolytic degradation and potential role of onconeural protein cdr2 in neurodegeneration.
Hwang JY, Lee J, Oh CK, Kang HW, Hwang IY, Um JW, Park HC, Kim S, Shin JH, Park WY, Darnell RB, Um HD, Chung KC, Kim K, Oh YJ., Free PMC Article | 10/14/2017 |
| Onconeuronal antigen Cdr2 correlates with HIF prolyl-4-hydroxylase PHD1 and worse prognosis in renal cell carcinoma. | Onconeuronal antigen Cdr2 correlates with HIF prolyl-4-hydroxylase PHD1 and worse prognosis in renal cell carcinoma.
Kaufmann MR, Schraml P, Hermanns T, Wenger RH, Camenisch G. | 07/6/2013 |
| This study shows a very high frequency of HER2 overexpression in breast cancers in patients with anti-Yo-associated paraneoplastic cerebellar degeneration. | Human epidermal growth factor receptor 2 overexpression in breast cancer of patients with anti-Yo--associated paraneoplastic cerebellar degeneration.
Rojas-Marcos I, Picard G, Chinchón D, Gelpi E, Psimaras D, Giometto B, Delattre JY, Honnorat J, Graus F., Free PMC Article | 08/18/2012 |
| The association between Yo and CCDC104 antibodies in paraneoplastic neurological syndromes may indicate functional similarities. | Antibody to CCDC104 is associated with a paraneoplastic antibody to CDR2 (anti-Yo).
Totland C, Bredholt G, Haugen M, Haukanes BI, Vedeler CA. | 04/23/2011 |
| The results suggest that Yo antibodies are not only related to the expression of CDR2 alone, but also to immune dysregulation. | CDR2 antigen and Yo antibodies.
Totland C, Aarskog NK, Eichler TW, Haugen M, Nøstbakken JK, Monstad SE, Salvesen HB, Mørk S, Haukanes BI, Vedeler CA., Free PMC Article | 03/5/2011 |
| Clinical trial of gene-disease association and gene-environment interaction. (HuGE Navigator) | Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score.
Rose JE, Behm FM, Drgon T, Johnson C, Uhl GR., Free PMC Article | 06/30/2010 |
| Cdr2 protein strongly accumulates in papillary renal cell carcinoma, attenuates the HIF response to tumor hypoxia and may become of diagnostic importance as novel renal tumor marker. | Onconeuronal cerebellar degeneration-related antigen, Cdr2, is strongly expressed in papillary renal cell carcinoma and leads to attenuated hypoxic response.
Balamurugan K, Luu VD, Kaufmann MR, Hofmann VS, Boysen G, Barth S, Bordoli MR, Stiehl DP, Moch H, Schraml P, Wenger RH, Camenisch G. | 01/21/2010 |
| Identifies c-Myc interaction with cdr2 by co-IP and co-localization in cytoplasm of cerebellar Purkinje neurons. Sera from 6/6 patients with cdr2 autoantibodies and paraneoplastic cerebellar degeneration block this interaction. | The cytoplasmic Purkinje onconeural antigen cdr2 down-regulates c-Myc function: implications for neuronal and tumor cell survival.
Okano HJ, Park WY, Corradi JP, Darnell RB., Free PMC Article | 05/9/2008 |
| Identifies cdr2-specific T cells in patients with paraneoplastic cerebellar degeneration; cells are evident by standard CTL, and by cross-presentation of apoptotic cdr2-expressing cells. | Tumor-specific killer cells in paraneoplastic cerebellar degeneration.
Albert ML, Darnell JC, Bender A, Francisco LM, Bhardwaj N, Darnell RB. | 05/9/2008 |
| Mycoplasma fermentans, in infecting human B cells, generates a Mycoplasma component that interacts with CD21, which is involved in B cell proliferation. | Infection of human B lymphoma cells by Mycoplasma fermentans induces interaction of its elongation factor with the intracytoplasmic domain of Epstein-Barr virus receptor (gp140, EBV/C3dR, CR2, CD21).
Balbo M, Barel M, Lottin-Divoux S, Jean D, Frade R. | 01/21/2010 |
| In patients with paraneoplastic cerebellar degeneration and anti-Yo antibodies, IFN-gamma-secreting cell responses towards Cdr2 isoforms are not detected, suggesting a limited role for cytotoxic T lymphocyte-mediated tumor immunity in this patient group. | An interferon-gamma ELISPOT and immunohistochemical investigation of cytotoxic T lymphocyte-mediated tumour immunity in patients with paraneoplastic cerebellar degeneration and anti-Yo antibodies.
Sutton IJ, Steele J, Savage CO, Winer JB, Young LS. | 01/21/2010 |